Limit search to available items
E-book
Author Donghi, Monica, author

Title Patent strategy in pharmaceutical industry : are additional patents valuable? / Monica Donghi
Edition 1. Auflage
Published Baden-Baden : Nomos, 2014

Copies

Description 1 electronic resource (84 pages )
Series MIPLC studies ; volume 20
MIPLC studies ; volume 20.
Contents Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices
F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German
Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others
Summary Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20
Analysis Markenrecht
Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht
Gewerblicher Rechtsschutz
Notes Originally presented as author's thesis (LL.M.)--Munich Intellectual Property Law Center, 2012
Bibliography Includes bibliographical references (pages 77-84)
Notes English
Description based on print version record; resource not viewed
Subject Drugs -- Patents -- Economic aspects -- European Union countries
Patent medicines -- Law and legislation -- European Union countries
Patent medicines -- European Union countries -- Case studies
Drugs -- Patents
LAW -- Commercial -- General.
Patent medicines
Patent medicines -- Law and legislation
European Union countries
Genre/Form Case studies
Form Electronic book
LC no. 2020719250
ISBN 9783845251288
384525128X